171 related articles for article (PubMed ID: 8133004)
1. Measles-mumps-rubella immunization of susceptible hospital employees during a community measles outbreak: cost-effectiveness and protective efficacy.
Stover BH; Adams G; Kuebler CA; Cost KM; Rabalais GP
Infect Control Hosp Epidemiol; 1994 Jan; 15(1):18-21. PubMed ID: 8133004
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
Ferson MJ; Robertson PW; Whybin LR
Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
4. A benefit-cost analysis of two-dose measles immunization in Canada.
Pelletier L; Chung P; Duclos P; Manga P; Scott J
Vaccine; 1998; 16(9-10):989-96. PubMed ID: 9682349
[TBL] [Abstract][Full Text] [Related]
5. Measles, mumps, and rubella vaccines.
Wharton M; Cochi SL; Williams WW
Infect Dis Clin North Am; 1990 Mar; 4(1):47-73. PubMed ID: 2407778
[TBL] [Abstract][Full Text] [Related]
6. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
Bart KJ; Orenstein WA; Hinman AR
Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
[TBL] [Abstract][Full Text] [Related]
7. Screening hospital employees for measles immunity is more cost effective than blind immunization.
Sellick JA; Longbine D; Schifeling R; Mylotte JM
Ann Intern Med; 1992 Jun; 116(12 Pt 1):982-4. PubMed ID: 1586108
[TBL] [Abstract][Full Text] [Related]
8. Quality standard for assurance of measles immunity among health care workers. Infectious Diseases Society of America.
Krause PJ; Gross PA; Barrett TL; Dellinger EP; Martone WJ; McGowan JE; Sweet RL; Wenzel RP
Clin Infect Dis; 1994 Mar; 18(3):431-6. PubMed ID: 8011829
[TBL] [Abstract][Full Text] [Related]
9. Benefits, risks and costs of immunization for measles, mumps and rubella.
White CC; Koplan JP; Orenstein WA
Am J Public Health; 1985 Jul; 75(7):739-44. PubMed ID: 3923849
[TBL] [Abstract][Full Text] [Related]
10. Mumps incidence in Israel--impact of MMR vaccine.
Slater PE; Roitman M; Costin C
Public Health Rev; 1990-1991; 18(1):88-93. PubMed ID: 2132885
[TBL] [Abstract][Full Text] [Related]
11. Quality standard for assurance of measles immunity among health care workers. The Infectious Diseases Society of America.
Krause PJ; Gross PA; Barrett TL; Dellinger EP; Martone WJ; McGowan JE; Sweet RL; Wenzel RP
Infect Control Hosp Epidemiol; 1994 Mar; 15(3):193-9. PubMed ID: 8207178
[TBL] [Abstract][Full Text] [Related]
12. MMR vaccine--one year on.
Walker D
Practitioner; 1990 May; 234(1489):550-2. PubMed ID: 2392406
[No Abstract] [Full Text] [Related]
13. Measles outbreak in Fife: which MMR policy?
Carter H; Gorman D
Public Health; 1993 Jan; 107(1):25-30. PubMed ID: 8475240
[TBL] [Abstract][Full Text] [Related]
14. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
15. Pancreatitis caused by measles, mumps, and rubella vaccine.
Adler JB; Mazzotta SA; Barkin JS
Pancreas; 1991 Jul; 6(4):489-90. PubMed ID: 1876605
[TBL] [Abstract][Full Text] [Related]
16. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
17. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
[TBL] [Abstract][Full Text] [Related]
19. Two doses of measles mumps rubella (MMR) vaccine.
Kuno-Sakai H; Ozaki K; Kimura M
Acta Paediatr Jpn; 1989 Dec; 31(6):690-7. PubMed ID: 2516395
[TBL] [Abstract][Full Text] [Related]
20. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine].
Takayama N; Kidokoro M; Suzuki K; Morita M
Kansenshogaku Zasshi; 1992 Jun; 66(6):776-80. PubMed ID: 1331262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
